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Abstract. An RNA virus from the Coronaviridae family, a subgroup of Coronavirinae, was first 
identified in late 2019 as the cause of severe acute respiratory infection in China.1 Despite the fact that 
clinical guidelines have been developed for the treatment of a new coronavirus infection, there are 
currently no specific medicine of preventing and treating a new coronavirus infection.2 
Various viral proteins are considered among drug targets, including: RNA-dependent RNA 
polymerase, papain-like protease, main protease and viral surface proteins (S-protein and TMPRSS2).2 
The main protease is a promising drug target because it is required for protein processing and viral 
replication.2 In this study, molecular docking of 56 ligands with clinically proven inhibitory action against 
heterogeneous group of enzymes was carried out in order to study the possibility of inhibiting the main 
protease SARS-CoV-2 (PBD ID: 6LU7, resolution 2.16 Å). SARS coronavirus 3CL protease (PBD ID: 
2GX4, resolution 1.93 Å) was selected as a control macromolecule. Molecular docking and assessment 
of binding sites were performed using AutoDock Tools 1.5.6 software. The results are shown in Table 1. 
 
Table 1. Molecular docking results with SARS-CoV-2 major protease 
 
Strong binding energy, small cluster sizes Weak binding energy, large cluster sizes 
Ligand’s 
INN 
Binding E, kkal/mol; number of 
conformations in the largest 
cluster 
Ligand’s INN E связывания, ккал/моль; 
number of conformations in the 
largest cluster 
Caspofungin -15,31; 2 Isophlurophate -4,09; 23 
Saquinavir -14,14; 4 Riamilovir -6,02; 70 
Nelfinavir -13,33; 5 Captopril -6,31; 15 
Indinavir -12,76; 2 Mefloquine -6,90; 37 
Remikiren -13,67; 2 Ribavirin -8,01; 12 
 
Thus, the best potential medical drugs – coronavirus's protease inhibitors among compounds 
explored may be heterogenic group molecules (antiviral agents, indirect anticoagulants, as well as 
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